Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The difference is IPIX has a drug (possibly drugs with K) that makes a lot of very profitable drugs obsolete.
Brilacidin is the new:
Antiviral
Antibiotic
Anti inflammatory
IBD
Add in K
Kevetrin modulates the P53 gene!
Add it all up. How many dollars are at stake for these huge multinationals.
It’s no surprise very powerful companies would want to stop this otc biotech.
I get your point this is the OTC but technically this is from the RBL not the company. And this was not hot air. It’s helium! This was at half the dose of the ABSSSI phase two trial! Safety confirmation! All viruses with an outer protective membrane are put on notice. Brilacidin’s coming and it will eventually be in multiple delivery systems. IMO.
“Innovation Pharmaceuticals’ Brilacidin Inhibits Novel Coronavirus (COVID-19) by Almost 90% at the Lowest Concentration Tested to Date in a Human Lung Cell Line”.
IPIX came up with the idea of possibly using an inhaler not another message board poster. Check Page 11 of the corporate update. PDF’d on their website.
All good. I just wanted to make sure the newer ones understood. I know you already know. And it’s a good excuse to show what IPIX will return too when they have financing.
For the record here’s the reason daptomycin was compared. Compared in an actual Phase 2 study and not just a PR.
“On October 23rd 2014, Cellceutix announced positive top-line results for the randomized double-blind study comparing three dosing regimens of Brilacidin to daptomycin for the treatment of ABSSSI. The primary endpoint, defined as reduction of at least 20% in area of ABSSSI lesion, relative to baseline, was achieved in the intent-to-treat (ITT) population at 48-72 hours, for each of the three Brilacidin dosing regimens, including two single-dose regimens, with results that were comparable to the FDA-approved seven-day dosing regimen of daptomycin.”
Or you work for Leviston and you post in all CAPs under multiple alias
I completely understand where you’re coming from and glad to see you posting. Keep it up!
I don’t know. I didn’t get to see the link. I trust the person that has been stickied based on their posting track record. So I’m going with that. Sorry I don’t trust a bunch of newish names of supposed longs. In the past there’s been a few that turned out to be merely traders disguised as longs. They still show up to post to this day. Some of us forgive we just don’t forget. Just hoping it turns out the way it’s being presented.
And why didn’t IPIX PR this upcoming meeting? I really hope this scooby doo sleuthing that was done is true. My only guess to why Leo did not PR it is because he wanted the day traders to sell their shares and also the supposed shorters to be left flat footed when the grant news hits. That’s why he said nothing about grants in the last two PR’s and instead put the timeline up for all of them to sell out thinking they could return in the 4th qtr. But if that was Leo’s plan it’s been ruined by well intentioned longs who couldn’t keep their news to themselves. So we wait and see...
No problem. Just trying to spread the future gains. From your list it looks like you’re doing just fine in that department. Especially with NVAX. What a run!
If you change your mind Brilacidin is the real deal therapeutic IMO. The covid virus’s only weakness is in its surrounding membrane. Anything that can poke a hole in that membrane kills it. Take another look at Brilacidin’s MOA. Or don’t. Maybe someone else will. GL.
I’m printing up the “I PICK IPIX” bumper stickers right now.
Is it too late to get IPIX on the ballot? IPIX 2020. I sure would like a third option. Maybe Brilacidin can poke a hole in the moron membrane surrounding our country.
I like this line from the article you posted the best. I’ll leave everyone here who knows the MOA of Brilacidin to fill in the blank.
“But the coronavirus has a weakness: an outer membrane that can be destroyed by”...
They haven’t owned brilacidin for 12 years.
Keep in mind that Brilacidin should also work after infection has already taken place when the virus burst the cell and tries to spread. It should stop the spread through it’s MOA’s.
Billion dollar fund for new antibiotics. Billions for covid. Brilacidin is a superstar playing in the minor leagues waiting for the oblivious coach to move it into the majors...
All about the MOA’s. When the covid virus eventually burst the cell it is vulnerable to brilacidin’s mechanism of action. Pop goes the virus cuz the virus goes pop. Stopped dead in its track. Viral load reduced 95 to 97% in lung. 85% in kidney when exposed to B. IV treatment of Brilacidin is a game changer IMO. Gold standard in CEO’s opinion. Worthy of future studies and multiple peer reviewed journal articles in RBL’s scientific findings...
And there it is. Thank you for verifying my suspicions.
What do you mean by “we”? Who is this “we” that you speak of? What is the definition of “we”? If there is no relationship between one entity and another besides a message board does that still count as “we”? How much we can a wechuck we if a wechuck could chuck we? Asking for a friend. We both want to know.
No one is waiting for GMU. It’s bonus data.
June 17th 2020
“Testing results observed to date formed the basis for a federal grant application that was submitted last week by the RBL, in collaboration with the Company, proposing to evaluate Brilacidin’s potential as a pan-coronavirus therapeutic, with possible extension into other viruses. The Company is in the process of manufacturing Brilacidin for intravenous (IV) dosing and will be seeking FDA guidance for a planned COVID-19 clinical study.”
Just have to click on your own name and all your post come up. Easier search. Here it is. Posting this cuz I wanna see if you go 2 for 2. If you do I’ll be sending you my info. Lol! Plus it says Uranus Sextile. I have no idea what that means but it sure makes me giggle. Lol! I know I know. Grow up! I refuse...
dp70
“Week of June 15th; one day within June 30th; one day within July 9th; and July and August transit Uranus sextile (good news aspect) for the entire 2 months. Of course news won’t be a continuous 60 days but there will be enough news to muzzle the cry babies so Brilacidin can do its work. I hope the CB’s sell their shares soo so there will be more for the believers.”
After looking into CYDY I can’t believe people complain about Leo and IPIX. According to OTCmarkets. Almost 530,000,000 OS compared to Almost 300,000,000 for IPIX. How is that stock so high? Yeah yeah funding. But still. If it’s any indication of what’s in store for IPIX what are the masses waiting for? Deal of the decade going on here. Some us have realized a long time ago and continue to buy but it seems so obvious at this point. Tell a friend or your family. Share the run that’s about to happen. AJMO. Good luck.
Totally agree. Well said. People tend to paint with broad strokes thinking every OTC is a PnD and should be traded and not worth investing in. This philosophy ends up hurting the real companies who add actually value to the world and only use the OTC as a necessary vehicle to take them to the next level. The OTC also provides the opportunity for those not born with a silver spoon to weed through the junk that does litter the OTC to find the gems that also sit buried waiting to be revealed to the world. Good luck to all fellow investors.
Thanks for your contribution to the board. Nice addition. A little history for perspective. Before the Mako take down the CEO was frugal with raising capital. A little too much actually IMO. He missed opportunities to raise funds at a higher stock price because of his frugality. But no one saw what was coming so I can understand his mindset of not being in a rush to dilute the current shareholders to raise a war chest. Things were humming along before the coordinated attacks. To survive he’s done what he’s had to do. Which is dilute the old school longs to where we are now. Could have been worse faced with what IPIX has been faced with. But I’m not too concerned going forward with his decision making process of when and how much to raise. I think he’s learned a valuable lesson going through what he has. I think we all have. Lol!
“Pound the table”!!! RIP to all the old school posters not here to enjoy this time. Still waiting to see if Biohedge shows up again...
Since there is no (IMO) legitimate current standard treatment for Covid to compare Brilacidin to. Because of B’s established safety record I think when phase two is successful the FDA will allow B to go straight to phase 4. It’s too needed to delay longer then necessary. Current administration will be desperate to have a treatment before election. JMO. Stay tuned...
Great reminder for all the new investors. Here’s a favorite quote by one of its inventors about what you’re alluding to. The potential beyond just being the Gold standard for Covid.
“We've tested them against more than 25 different bacterial strains, including strains of bacteria that are resistant to antibiotics, and they work against all of them. They also have antifungal and antiviral properties and are very inexpensive and very easy to make. They're safe, selective for bacterial cells, and don't harm mammalian cells. Polymer derivatives of these compounds have been made, and we've shown that we can add them to paints, plastics and textiles to create products and surfaces that are intrinsically and permanently self-sterilizing by virtue of the material itself”.
The material itself will not support the growth of bacteria or let a virus live on it!
How much is that worth?
You’re a class act. Congrats to you! Thanks for the PM.
Still waiting to hear your expert opinion on kevetrin. P53 modulation! Chemosensitizer in preclinical. Take a deep dive when you get a chance. K deserves a look.
Great day today longs! Keep on the sunny side...
And these were the new results from the latest trial.
“Brilacidin
· Demonstrates potent and rapid virucidal activity
· Experiment supports Brilacidin’s therapeutic potential as a COVID-19 treatment and as a prophylactic agent against COVID-19
WAKEFIELD, MA – May 19, 2020 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today that its anti-SARS-CoV-2 (COVID-19) drug candidate, Brilacidin, in an in vitro experiment using VERO cells, reduced the viral titer (load) of SARS-CoV-2 by 75 percent after only 1 hour of preincubation prior to infection at a concentration of 10µM as compared to vehicle control.
These statistically significant lab results strongly support Brilacidin’s prophylactic treatment potential given the drug’s potent and rapid virucidal activity—a unique ability, different from any other known drug currently in development to treat COVID-19, to inactivate the novel coronavirus prior to host cell entry and subsequent viral replication. A majority of antiviral agents targeting SARS-CoV-2 attempt to inhibit viral replication rather than completely eliminating the virus (virustatic versus virucidal).
Additional time-dependent and concentration-dependent experiments are underway to further delineate Brilacidin’s virucidal properties against SARS-CoV-2”.
Everything clear now?
There seems to still be some confusion. I’m now sure that this is on purpose. Somebody is still claiming yesterday’s PR is old data. It is not old Data. Yesterday’s results are from this study.
“WAKEFIELD, MA – May 5, 2020 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report the Company has executed a Material Transfer Agreement (MTA) with a leading U.S.-based Public Health Research Institute, with access to a Biosafety Level-3 (BSL-3) laboratory, to evaluate the immunomodulatory and antiviral properties of Brilacidin in relation to COVID-19. This new research is separate from the previously announced antiviral studies being conducted at a U.S. Regional Biocontainment Laboratory (RBL), which over the weekend informed us that the next phase of Brilacidin testing has commenced.
Scientists at the Public Health Research Institute plan to evaluate Brilacidin’s inhibitory effect on SARS-CoV-2 viral replication in primary immune mediators (peripheral blood mononuclear cells, T cells, B cells, monocytes, macrophages) obtained from both young and old donors to assess age-dependent host responses to the novel coronavirus. Brilacidin drug substance has been received by the Institute and is now available for testing”.
New trial study results. New data. More evidence of Brilacidin’s potential.
What’s really going on? Testing in human lung samples in both the elderly and the young at multiple doses apparently takes more time then some monkey cells. Which took two weeks to get results.
Is this some kind of joke? It was data from a completely different trial at a completely different lab.
Lol! Good advice! Fingers crossed...
Better to say nothing and be thought of as a fool then open your mouth and be known as one.
And these were the new results from the latest trial.
“Brilacidin
· Demonstrates potent and rapid virucidal activity
· Experiment supports Brilacidin’s therapeutic potential as a COVID-19 treatment and as a prophylactic agent against COVID-19
WAKEFIELD, MA – May 19, 2020 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today that its anti-SARS-CoV-2 (COVID-19) drug candidate, Brilacidin, in an in vitro experiment using VERO cells, reduced the viral titer (load) of SARS-CoV-2 by 75 percent after only 1 hour of preincubation prior to infection at a concentration of 10µM as compared to vehicle control.
These statistically significant lab results strongly support Brilacidin’s prophylactic treatment potential given the drug’s potent and rapid virucidal activity—a unique ability, different from any other known drug currently in development to treat COVID-19, to inactivate the novel coronavirus prior to host cell entry and subsequent viral replication. A majority of antiviral agents targeting SARS-CoV-2 attempt to inhibit viral replication rather than completely eliminating the virus (virustatic versus virucidal).
Additional time-dependent and concentration-dependent experiments are underway to further delineate Brilacidin’s virucidal properties against SARS-CoV-2”.
Everything clear now? Is anyone still confused?
There seemed to be some confusion earlier. Not sure if that was on purpose. Somebody even claimed todays PR was old data. It is not old Data. Today’s results are from this study.
“WAKEFIELD, MA – May 5, 2020 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report the Company has executed a Material Transfer Agreement (MTA) with a leading U.S.-based Public Health Research Institute, with access to a Biosafety Level-3 (BSL-3) laboratory, to evaluate the immunomodulatory and antiviral properties of Brilacidin in relation to COVID-19. This new research is separate from the previously announced antiviral studies being conducted at a U.S. Regional Biocontainment Laboratory (RBL), which over the weekend informed us that the next phase of Brilacidin testing has commenced.
Scientists at the Public Health Research Institute plan to evaluate Brilacidin’s inhibitory effect on SARS-CoV-2 viral replication in primary immune mediators (peripheral blood mononuclear cells, T cells, B cells, monocytes, macrophages) obtained from both young and old donors to assess age-dependent host responses to the novel coronavirus. Brilacidin drug substance has been received by the Institute and is now available for testing”.
New trial study results. New data. More evidence of Brilacidin’s potential.
Old Chinese saying.
The early bird gets the worm, but the second mouse gets the cheese.
I thought B would only be used as a potential adjunct to a vaccine. Basically an additive. But for the record the PR did not state it was a failure.
This is what matters. IMO
“While the vaccine pathway remains of interest, the Company is prioritizing Brilacidin’s clinical development as a potential novel COVID-19 treatment, and thus is taking steps to rapidly advance Brilacidin into human trials”.
Human trials!